Cerevel Therapeutics Holdings, Inc. (CERE) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Ronald C. Renaud Jr.,.
CERE has IPO date of 2020-07-30, 355 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $8.19B.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases including schizophrenia, epilepsy, Parkinson's disease, and psychiatric disorders. The company's pipeline includes several lead programs in clinical development, such as emraclidine for schizophrenia, Darigabat for drug-resistant epilepsy and anxiety, and Tavapadon for Parkinson's disease, alongside multiple earlier-stage candidates targeting conditions like dementia-related apathy, substance use disorder, and major depressive disorder. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cerevel leverages multiple molecular mechanisms and receptor targets to address critical unmet needs in central nervous system disorders.
